Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
NCT03635892 trial: what clinicians have said so far
A Study of Nivolumab In Combination With Cabozantinib in Patients With Non-Clear Cell Renal Cell Carcinoma
- NCT03635892 ↗
- Active, not recruiting
- Memorial Sloan Kettering Cancer Center
- Focused size, estimated: 1–150 verified statements once built
We haven't built an HCP commentary report on NCT03635892 (cabozantinib plus nivolumab in advanced or metastatic non-clear cell renal cell carcinoma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NCT03635892 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 3 posts on X, typically up to 13 once built |
The trial
ClinicalTrials.gov- Official title
- A Phase 2 Open-Label Study of Nivolumab Combined With Cabozantinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma (CA209-9KU)
- Phase
- Phase 2
- Status
- Active, not recruiting
- Conditions
- Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma; Unclassified Renal Cell Carcinoma; Papillary Renal Cell Carcinoma; Fumarate Hydratase Deficient Renal Cell Carcinoma; Succinate Dehydrogenase Deficient Renal Cell Carcinoma; Collecting Duct Renal Cell Carcinoma; Chromophobe Renal Cell Carcinoma
- Interventions
- cabozantinib; nivolumab
- Arms
- Cohort 1: Unclassified, papillary, and HL RCC · Experimental
- Cohort 2: Chromophobe RCC · Experimental
- Cohort 3: Unclassified, papillary, and HL RCC · Experimental
- Cohort 4: Unclassified, papillary, and HL RCC · Experimental
- Enrollment
- 60
- Primary outcomes
- objective response rate
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Aug 13, 2018
- Primary completion
- Aug 2027 (estimated)
- Results posted
- No
- Registry record
- NCT03635892 · updated Sep 21, 2026
Publications
linked from the registry- Lee CH, Voss MH, Carlo MI, Chen YB, Zucker M, Knezevic A, Lefkowitz RA, Shapnik N, Dadoun C, Reznik E, Shah NJ, Owens CN, McHugh DJ, Aggen DH, Laccetti AL, Kotecha R, Feldman DR, Motzer RJ. Phase II Trial of Cabozantinib Plus Nivolumab in Patients With Non-Clear-Cell Renal Cell Carcinoma and Genomic Correlates. J Clin Oncol. 2022 Jul 20;40(21):2333-2341. doi: 10.1200/JCO.21.01944. Epub 2022 Mar 17. PubMed 35298296